Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Milei Threatens Falkland Oil Firms With Sanctions 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Add as a preferred source on Google
MOUNTAIN VIEW, Calif., Feb. 20, 2018 -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the fourth quarter and full year 2017 after the close of trading on Thursday, March 8, 2018. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET.
Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 8195624. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.iridex.com. A telephone replay will also be available beginning Thursday, March 8, 2018 through Friday, March 9, 2018 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 8195624.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
